New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RHHBY;ILMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 22, 2015
08:58 EDTILMNIllumina weakness a buying opportunity, says Cowen
Subscribe for More Information
07:52 EDTILMNIllumina downgraded to Neutral from Buy at Janney Capital
07:44 EDTILMNIllumina price target lowered to $250 from $275 at Canaccord
Subscribe for More Information
05:45 EDTILMNIllumina should be bought on post-earnings selloff, says Mizuho
Subscribe for More Information
July 21, 2015
19:00 EDTILMNOn The Fly: After Hours Movers
Subscribe for More Information
16:24 EDTILMNIllumina drops sharply after results
Subscribe for More Information
16:16 EDTILMNIllumina reports Q2 cash flow from operations of $171M, free cash flow $130M
16:15 EDTILMNIllumina reports Q2 gross margin 69.8% vs. 67.1% a year ago
16:15 EDTILMNIllumina raises FY15 adjusted EPS view to $3.39-$3.45 from $3.36-$3.42
Subscribe for More Information
16:13 EDTILMNIllumina reports Q2 adjusted EPS 80c, consensus 77c
Subscribe for More Information
15:02 EDTILMNNotable companies reporting after market close
Subscribe for More Information
07:05 EDTRHHBYOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information
July 20, 2015
07:33 EDTRHHBYInternational AIDS Society to hold a conference
Subscribe for More Information
06:17 EDTILMNMizuho sees Q2 earnings beats in Diagnostics space
Subscribe for More Information
05:13 EDTRHHBYRoche expands HIV Global Access Program
Roche announced an expansion to the HIV Global Access Program to include early infant HIV diagnostic testing for low and middle income countries. Roche, in partnership with the Joint United Nations Programme on HIV/AIDS, or UNAIDS, the Clinton Health Access Initiative, or CHAI, UNITAID, the U.S. President's Emergency Plan For AIDS Relief, or PEPFAR, and the Global Fund to fight AIDS, TB and Malaria, is committed to working with the Diagnostics Access Initiative by providing state-of-the-art solutions to achieve the 90-90-90 goal set forth by UNAIDS. Announced in 2014, the HIV Global Access Program is Roche's most recent addition to the AmpliCare Initiative, which launched in 2002 in South Africa.
July 17, 2015
10:05 EDTILMNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTILMNIllumina initiated with a Buy at Canaccord
Subscribe for More Information
July 16, 2015
06:33 EDTILMNIllumina launches large-scale genome sequencing solution SeqLab
Subscribe for More Information
06:08 EDTILMNPiper says buy Illumina on weakness despite mixed checks
Subscribe for More Information
July 14, 2015
06:04 EDTRHHBYRoche says atezolizumab met primary endpoint in IMvigor 210 trial
Roche announced that in the IMvigor 210 study, the investigational cancer immunotherapy atezolizumab shrank tumors -- objective response rate, ORR, the primary end point of this Phase II study -- in people with locally advanced or metastatic urothelial bladder cancer who had progressed on initial treatment. High amounts of PD-L1 expression by a person’s cancer correlated with increased response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab. Sandra Horning, M.D., chief medical officer and head of Global Product Development, said, “We plan to present results at an upcoming medical meeting and will discuss next steps with health authorities to bring a new treatment option to patients as soon as possible.” Last year, the U.S. FDA granted Breakthrough Therapy Designation for atezolizumab in people whose metastatic bladder cancer expressed PD-L1. This designation is designed to expedite the development and review of medicines intended to treat serious diseases. In addition to the IMvigor 210 study, Roche has an ongoing randomised Phase III study, IMvigor 211, comparing atezolizumab with standard-of-care chemotherapy in people who have relapsed UBC, and a planned Phase III study, IMvigor 010, that will evaluate atezolizumab compared with observation in people with early-stage muscle-invasive bladder cancer who are selected for PD-L1 expression and are at risk for recurrence.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use